Endologix (NASDAQ: ELGX) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Endologix to similar businesses based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, dividends, valuation and risk.
Valuation & Earnings
This table compares Endologix and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Endologix||$192.93 million||-$154.67 million||-6.20|
|Endologix Competitors||$1.67 billion||$207.58 million||87.31|
Institutional and Insider Ownership
54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 4.1% of Endologix shares are owned by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Endologix and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Endologix and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix presently has a consensus target price of $5.36, indicating a potential downside of 7.16%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.49%. Given Endologix’s peers stronger consensus rating and higher possible upside, analysts clearly believe Endologix has less favorable growth aspects than its peers.
Risk and Volatility
Endologix has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Endologix’s peers have a beta of 0.47, meaning that their average share price is 53% less volatile than the S&P 500.
Endologix peers beat Endologix on 8 of the 12 factors compared.
Endologix Company Profile
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.